Single User PDF
GBP 1699.00  

PDF Departmental License
GBP 2999.00  

PDF Site License
GBP 4999.00  

PDF Global Site License
GBP 6999.00  

UK Head Office
+44(0)1494 771734
or Buy Now! online

Hot Reports:
Brazil Healthcare - New Opportunities for Growth


US Non-Invasive Prenatal Diagnostics - Market Insight


Global Genetic Testing Market Forecast to 2015


US Clinical Laboratory Testing Market Assessment


US Cardiac Device Market Analysis


Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022


In Vitro Diagnostics: World Market Outlook 2012-2022


Pharma Wholesale and Distribution Market: World Outlook 2012-2022

Table of Contents

Management Report
Published: May 2012
Pages: 183
Tables: For full details, please email deborahf@cmsinfo.com
From: GBP 1699.00  Buy Now!
Research from: pharmaceuticalmarketresearch
Sector: Indication Areas

Where is the hepatitis treatment market heading? Visiongain's new report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.

This study investigates drugs and vaccines for treating hepatitis - existing and pipeline products. You assess projected sales at world market, therapeutic submarket, product and national level to 2022.

You see forecasting of therapeutic submarkets to 2022, finding potential revenues:
• Hepatitis B
• Hepatitis C.

You also find revenue forecasting of product classes to 2022:
• Oral antivirals
• Interferons
• Vaccines.

How will 10 leading products - including Baraclude, Pegasys, Incivek and PegIntron - perform from 2012? Our investigation gives you business research and analysis with sales forecasts for leading brands. You discover their growth potential.

The market is changing. You find discussions of treatments in development, by phase and indication. In the study you also see predictions of launch times for product candidates.

Market value for 2012 and prospects for the future

What does the future hold? The pharma industry will improve treatments for hepatitis and increase revenues there from 2012 to 2022. In particular, the R&D pipeline for hepatitis C is strong and promising. World revenues will grow to $8.7bn in 2012, our analysis shows.

We estimate that more than 15 new therapies will reach the market by 2016. Almost all of those pipeline candidates are oral direct-acting antivirals. You see opportunities there.

What about companies? Our work discusses Roche, GSK, Bristol-Myers Squibb, Merck, Novartis and many other pharmaceutical manufacturers, analysing prospects of the industry.

The main goal for hepatitis C therapy is all-oral, interferon-free regimens with improved efficacy over present treatments. Companies are developing oral antiviral combinations, with launches expected towards the middle of this decade.

High rates of efficacy and barriers to resistance in leading treatments mean the world hepatitis B treatment market will grow strongly to 2016, our report predicts. Generic competition will become noticeable afterwards, however.

Unmet treatment needs in hepatitis C, expanding vaccination programmes in emerging national markets, and increased virus screening will also stimulate the world market from 2012 onwards, we find.

Many commercial opportunities for hepatitis-treating agents exist, with high revenues possible to 2022. Our report shows you and explains.

Sales forecasts, market shares, developmental trends and discussions

In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 80 tables, 64 charts and a research interview.

Eight ways Hepatitis Treatments and Vaccines: World Market 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover projected revenue trends of 10 leading brands to 2022
• See market forecasting to 2022 for the US, Japan, EU5 countries, China and India
• Assess 7 leading companies, and other players, discovering activities and outlooks
• Review R&D pipelines, seeing trends by therapeutic area
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinions from the sector, seeing an interview with an external authority.

There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Top of Page